BMO Capital Initiates Coverage on Oncomed Pharmaceuticals Inc(NASDAQ:OMED). The shares have been rated Outperform. The rating by BMO Capital was issued on Apr 12, 2016.
In a different note, On Mar 9, 2016, JMP Securities said it Maintains its rating on Oncomed Pharmaceuticals Inc. In the research note, the firm Lowers the price-target to $21.00 per share. The shares have been rated ‘Market Outperform’ by the firm. On Jan 25, 2016, Leerink Swann said it Downgrades its rating on Oncomed Pharmaceuticals Inc. The shares have been rated ‘Market Perform’ by the firm.
Oncomed Pharmaceuticals Inc (OMED) made into the market gainers list on Fridays trading session with the shares advancing 0.88% or 0.1 points. Due to strong positive momentum, the stock ended at $11.51, which is also near the day’s high of $11.64. The stock began the session at $11.39 and the volume stood at 69,337 shares. The 52-week high of the shares is $27.74 and the 52 week low is $8.42. The company has a current market capitalization of $348 M and it has 3,02,76,057 shares in outstanding.
Oncomed Pharmaceuticals Inc(OMED) last announced its earnings results on Mar 10, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $6.84M. Analysts had an estimated revenue of $44.55M. Earnings per share were $1.50. Analysts had estimated an EPS of $0.41.
Several Insider Transactions has been reported to the SEC. On Jan 12, 2016, Jakob Dupont (SVP & Chief Medical Officer) sold 2,500 shares at $20.01 per share price.Also, On Jan 8, 2016, Austin Gurney (officer ) sold 2,162 shares at $21.72 per share price.On Jan 8, 2016, Timothy Hoey (SVP, Cancer Biology) sold 2,162 shares at $21.73 per share price, according to the Form-4 filing with the securities and exchange commission.
OncoMed Pharmaceuticals Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing protein therapeutics targeting cancer stem cells (CSCs). The Company’s product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state and also impact bulk tumor cells. Its technology is used to identify isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company is also engaged in discovering multiple product candidates that target fundamental biological pathways in immuno-oncology. Its products include Demcizumab AntiDLL4/VEGF bispecific Tarextumab AntiNotch1 Vantictumab Ipafricept Wnt 3rd Biologic Wnt Small Molecules and AntiRSPO.